Andrew C. von Eschenbach
Andrew C. von Eschenbach, M.D., is chairman of the Manhattan Institute's Project FDA. From September of 2005 to January 2009 he served as commissioner of the U.S. Food and Drug Administration where he championed an agenda to modernize the FDA. Dr. von Eschenbach joined FDA after serving for four years as director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum.
John F. Crowley, JD, MBA
John F. Crowley is chairman and CEO of Amicus Therapeutics, Inc. His involvement with biotechnology
stems from the 1998 diagnosis of two of his children with Pompe disease. In his drive to find a cure, Crowley left his position at Bristol-Myers Squibb and
founded Novazyme Pharmaceuticals. He and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer
prize-winning journalist Geeta Anand, The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children. He serves on the executive committee of the national board of directors of the Make-A-Wish Foundation of America and is a founding board member of the Global
Arthur Daemmrich, Ph.D., is an associate professor at the University of Kansas School of Medicine in the Department of History and Philosophy
of Medicine, with affiliations in the Department of Health Policy and Management and the Department of Preventive Medicine and Public Health.
His research examines historical dimensions of medical and public health risk management, especially the history of pharmaceutical regulation,
environmental health regulation, and chemical testing programs.
DiMasi, Ph.D., is Director of Economic Analysis at the Tufts
Center for the Study of Drug Development at Tufts University.
His research is focused on the new drug development and regulatory
review processes and the economics of the pharmaceutical industry.
Dr. DiMasi presents his work at numerous professional and
industry conferences in the United States and abroad and has
testified before the U.S. Congress in hearings leading up
to the FDA Modernization Act of 1997 and reauthorization of
the Prescription Drug User Fee Act.
Henry G. Grabowski
G. Grabowski, Ph.D., is a faculty member in the Health Sector
Management Program Faculty, a Professor of Economics and the
Director of the Program in Pharmaceuticals and Health Economics
at Duke University. Dr. Grabowski has published numerous studies
on the pharmaceutical industry with his principal research
involving the economics of the innovation process, business
regulation, industrial organization, and developing therapies
for Southern countries.
James J. Hsieh, M.D., Ph.D.
James J. Hsieh, M.D., Ph.D., is an associate member at the Human Oncology and Pathogenesis Program and an associate attending physician at the
Genitourinary Oncology Division at the Memorial Sloan-Kettering Cancer Center, and an associate professor at the Weill-Cornell Medical College. He was a
tenured faculty member at Washington University before joining the MSKCC in 2010. Dr. Hsieh obtained his M.D. in Taiwan, conducted his Ph.D. thesis at the
Johns Hopkins University, and finished his Medical Oncology Fellowship at the Dana-Farber Cancer Institute at Harvard Medical School. His clinical practice
and research focused on kidney cancer. He founded the Translational Kidney Cancer Research Program at the MSKCC in 2011.
Howard, Ph.D., is a senior fellow and the director of the
Manhattan Institute's Center for Medical Progress. He is also
the managing editor of MedicalProgressToday.com, a web magazine
that chronicles the connections between market-oriented public
policies and better access to more innovative health care.
He focuses his research on a wide variety of medical policy
issues, including medical innovation, FDA reform, and consumer-driven
Huber is a senior fellow at the Manhattan Institute writing on the issues of drug development, energy, technology, and the law. Huber is the author of the forthcoming book, The Cure in the Code: How 20th Century Law Is Undermining 21st Century Medicine (Basic Books, 2013.) He wrote The Bottomless Well, coauthored with Mark Mills, which Bill Gates said "is the only book I've ever seen that really explains energy, its history and what it will be like going forward".
P. Petrylak, M.D., is an Associate Professor of Medicine and the Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at the Columbia University Medical Center. Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunologicals section of the Food and Drug Administration Dr. Petrylak was instrumental in the clinical development of docetaxel for prostate cancer, and he chaired one of the trials that supported its approval for prostate cancer by the FDA in 2004. He was also one of the principal investigators on the SPARC trial, an international registration study of satraplatin, an oral chemotherapy agent, for patients who failed on chemotherapeutic regimen for prostate cancer
J. Philipson, Ph.D., is a professor at the Harris School
for Public Policy at the University of Chicago. He is an associate
member of the Department of Economics and has been a Senior
Lecturer at the Law School. Dr. Philipson's research focus
is on health economics. He served in the Bush Administration
as the Senior Economic Advisor to the head of the Food and
Drug Administration (FDA) during 2003-04, as the Senior Economic
Advisor to the head of the Centers for Medicare and Medicaid
Services (CMS) in 2004-05 and is currently serving on an eight
member health care task force for Senator John McCain's campaign
for President of the United States.
Lance K. Stell, Ph.D., FACFE, is the John and Mary West Thatcher
Professor of Philosophy, Davidson College, Davidson, NC, where
he serves as Director of the Medical Humanities Program. He
also holds appointments as Clinical Professor in the Department
of Internal Medicine, at Carolinas Medical Center, Charlotte,
NC, and as Full Professor (Adjunct), in the Translational
Science Institute, at Wake Forest University School of Medicine,
Winston-Salem, NC. Dr. Stell is a Fellow and Diplomate in the American College of Forensic Examiners. He consults
and serves as an expert witness in criminal and civil cases
in which the ethical standards of health care professionals
are implicated. He publishes in ethics, medical ethics and
philosophy of law. In 2005, the NC Medical Society recognized
Dr. Stell's service to the medical profession with the John
Huske Anderson award, the highest honor the Medical Society
bestows on a non-physician.
E. Fuller Torrey
E. Fuller Torrey MD is the Executive Director of the Stanley Medical Research Institute (SMRI) in Chevy Chase, Md. and the founder of the Treatment Advocacy Center in Arlington, VA. SMRI funds approximately 50 treatment trials at any given time for schizophrenia and bipolar disorder. Dr. Torrey was educated at Princeton, McGill and Stanford Universities and is the author of 20 books.
Andrew C. von Eschen